These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9856996)

  • 121. Location on heparin of the oligosaccharide section essential for anticoagulant activity.
    Radoff S; Danishefsky I
    J Biol Chem; 1984 Jan; 259(1):166-72. PubMed ID: 6706928
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin.
    Griffith MJ
    J Biol Chem; 1982 Jul; 257(13):7360-5. PubMed ID: 7085630
    [No Abstract]   [Full Text] [Related]  

  • 123. Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease.
    Lewis JH; Iammarino RM; Spero JA; Hasiba U
    Blood; 1978 Jan; 51(1):129-37. PubMed ID: 412531
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Reversible covalent direct thrombin inhibitors.
    Sivaraja M; Pozzi N; Rienzo M; Lin K; Shiau TP; Clemens DM; Igoudin L; Zalicki P; Chang SS; Estiarte MA; Short KM; Williams DC; Datta A; Di Cera E; Kita DB
    PLoS One; 2018; 13(8):e0201377. PubMed ID: 30071045
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Substantial non-electrostatic forces are needed to induce allosteric disruption of thrombin's active site through exosite 2.
    Mehta AY; Desai UR
    Biochem Biophys Res Commun; 2014 Sep; 452(3):813-6. PubMed ID: 25201728
    [TBL] [Abstract][Full Text] [Related]  

  • 126. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa.
    Verghese J; Liang A; Sidhu PP; Hindle M; Zhou Q; Desai UR
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4126-9. PubMed ID: 19540113
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Anticoagulant and signaling functions of antithrombin.
    Rezaie AR; Giri H
    J Thromb Haemost; 2020 Dec; 18(12):3142-3153. PubMed ID: 32780936
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Immunospecific analysis of in vitro and ex vivo surface-immobilized protein complex.
    Sask KN; Thong B; Goodarzynejad N; Berry LR; Chan AKC
    Biointerphases; 2022 Apr; 17(2):021005. PubMed ID: 35477241
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Anti-heparin activity of lysosomal cationic proteins from polymorphonuclear leukocytes.
    Saba HI; Roberts HR; Herion JC
    Blood; 1968 Mar; 31(3):369-80. PubMed ID: 5640632
    [No Abstract]   [Full Text] [Related]  

  • 130. Dynamic Combinatorial Optimization of
    Carbajo D; Pérez Y; Guerra-Rebollo M; Prats E; Bujons J; Alfonso I
    J Med Chem; 2022 Mar; 65(6):4865-4877. PubMed ID: 35235323
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Synthetic heparin fragments: new and efficient tools for the study of heparin and its interactions.
    Petitou M
    Nouv Rev Fr Hematol (1978); 1984; 26(4):221-6. PubMed ID: 6473093
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin.
    Rezaie AR; Giri H
    J Thromb Haemost; 2020 Mar; 18(3):528-533. PubMed ID: 32112532
    [No Abstract]   [Full Text] [Related]  

  • 133. Amide-functionalized 1,2,4-Triazol-5-amines as Covalent Inhibitors of Blood Coagulation Factor XIIa and Thrombin.
    Imberg L; Platte S; Erbacher C; Daniliuc CG; Kalinina SA; Dörner W; Poso A; Karst U; Kalinin DV
    ACS Pharmacol Transl Sci; 2022 Dec; 5(12):1318-1347. PubMed ID: 36524012
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Effect of endothelium on the anticoagulant activity of a covalent antithrombin-heparin complex.
    Atkinson HM; Stevic I; Berry LR; Chan AKC
    Sci Rep; 2024 Sep; 14(1):22335. PubMed ID: 39333740
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.
    Villari A; Giurdanella G; Bucolo C; Drago F; Salomone S
    Front Pharmacol; 2017; 8():480. PubMed ID: 28769809
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Heparan sulfate biosynthesis: a theoretical study of the initial sulfation step by N-deacetylase/N-sulfotransferase.
    Gorokhov A; Perera L; Darden TA; Negishi M; Pedersen LC; Pedersen LG
    Biophys J; 2000 Dec; 79(6):2909-17. PubMed ID: 11106599
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex.
    Berry L; Stafford A; Fredenburgh J; O'Brodovich H; Mitchell L; Weitz J; Andrew M; Chan AK
    J Biol Chem; 1998 Dec; 273(52):34730-6. PubMed ID: 9856996
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex.
    Paredes N; Wang A; Berry LR; Smith LJ; Stafford AR; Weitz JI; Chan AK
    J Biol Chem; 2003 Jun; 278(26):23398-409. PubMed ID: 12695507
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
    Stevic I; Berry LR; Chan AK
    J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
    Stevic I; Chan HH; Berry LR; Chander A; Chan AK
    J Biochem; 2013 Jan; 153(1):103-10. PubMed ID: 23100269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.